hVIVO reports revenue surge and expanding growth prospects

Specialist research group hVIVO has seen a significant rise in revenue for the first half of 2024, recording a 30.6% increase compared to the same period last year. The company generated £35.6 million in the first six months of this year, a notable jump from £27.3 million in 2023. Alongside this, EBITDA rose impressively by 67.6%, moving from £5.2 million to £8.7 million over the same period.

Earnings per share were also up, with adjusted earnings increasing 30.6%, rising from 62 pence to 81 pence. Furthermore, the company strengthened its cash reserves, which now stand at £37.1 million, compared to £31.3 million in June of the previous year.

Despite this strong performance, there has been a slight dip in the value of hVIVO’s weighted contracted order book, which has reduced from £78 million to £71 million. The company, headquartered in London, was acquired by Dublin-based Open Orphan five years ago.

The first half of 2024 saw hVIVO’s facility in Canary Wharf become fully operational. This period was marked by a record number of volunteers inoculated across six challenge trials and five challenge agents. The group also secured several key contracts, including a £6.3 million human rhinovirus contract with a biotech client and a £2.5 million Omicron characterisation study contract with a mid-sized pharmaceutical company.

In addition to these developments, hVIVO landed its largest field study to date, introducing a new revenue stream. Its subsidiary, Venn, also extended its multi-year consultancy agreement with major global pharmaceutical clients, further bolstering the company’s business prospects.

Chief Executive Officer, Yamin ‘Mo’ Khan, commented on the company’s strong performance, stating that hVIVO has entered the second half of the year with full visibility of its FY24 revenue guidance. He noted that the company continues to expand its pipeline not only in human challenge trials but also in other revenue streams such as clinical site studies, standalone laboratory services, and volunteer/patient recruitment.

Khan also highlighted ongoing operational improvements, driven by service expansion, increased automation, and the move to the new Canary Wharf facility. He reaffirmed hVIVO’s full-year revenue target of £62 million and revealed that the company is on track to capitalise on short to medium-term opportunities with a potential yield of £40 million. Looking further ahead, the group is aiming to achieve £100 million in revenue by 2028 through a combination of organic growth and selective acquisitions that align with its strategic and financial goals.

Former Chairman Cathal Friel made headlines in July when he sold his remaining shares in hVIVO for £6.1 million (€7.3 million). This move followed strong investor interest after the company’s recent capital markets event, further demonstrating the market’s confidence in hVIVO’s growth trajectory.

hVIVO continues to show strong financial performance and has laid out ambitious growth plans that indicate a bright future for the company. With a solid cash position, a fully operational facility, and a growing portfolio of contracts, hVIVO is poised for sustained success.

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    Inside hVIVO’s cutting-edge QA facility at Canary Wharf

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Virus portfolio for RSV research and development

    Respiratory Syncytial Virus (RSV), discovered in 1956, is a common and contagious RNA virus responsible for a range of respiratory illnesses worldwide. Initially identified by Dr. Robert Chanock and colleagues in chimpanzees, RSV belongs to the

    hVIVO plc

    Clinical trial eligibility: Pre-screening and Screening

    In clinical trials, ensuring patient safety is paramount, and researchers must identify suitable participants who meet specific requirements. To this end, there are distinct processes involved, known as pre-screening and screening, which help determine whether a

    hVIVO plc

    Connecting Airway Epithelial Cell Models with Human Challenge Studies

    Airway epithelial cells cultured in Air–Liquid Interface (ALI) conditions provide an environment that closely resembles the human airway system. This method facilitates improved oxygen availability and supports cellular differentiation, replicating the physiological conditions of the human

    hVIVO plc

    Esmée shares her FluCamp clinical trial volunteer experience

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Overcoming challenges in high-growth regulated industries

    The Navigating Risk podcast recently explored the challenges faced by high-growth businesses operating in highly regulated industries, particularly life sciences. Helen Yates, the Editor of Global Thought Leadership, engaged in a conversation with Mo Khan, the

    hVIVO plc

    Take a 360° interactive tour of a FluCamp Volunteer Room

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Clinical trial approval process in the UK

    The process of obtaining approval for clinical trials is comprehensive, as it involves multiple regulatory bodies that ensure the safety and efficacy of the medical interventions being tested. Researchers begin by meticulously planning the trial, outlining

    hVIVO plc

    hVIVO reports positive results from RSV antiviral human challenge trial

    hVIVO plc (LON:HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has noted the announcement by Enanta Pharmaceuticals, reporting positive topline results from

    hVIVO plc

    The importance of Clinical Trial Monitoring

    Monitoring is essential from the moment a clinical trial is planned until it concludes. This ensures that the study remains unbiased, patient safety is prioritised, and accurate results are achieved. The process of clinical trial monitoring

    hVIVO plc

    The future of vaccine development through human challenge trials

    Testing new treatments and vaccines often requires years, if not decades, to gather sufficient data. In response, scientists are turning to a more direct approach that involves deliberately infecting volunteers with potentially deadly pathogens. A notable

    hVIVO plc

    The impact of Clinical Trial results on medical advancements

    Clinical trials play a pivotal role in advancing the medical industry by allowing new treatments and interventions to be rigorously tested for both effectiveness and safety. Understanding how clinical trial data is used is essential to

    hVIVO plc

    Hvivo reports significant growth in earnings and revenue

    Hvivo, previously known as Open Orphan, saw a significant increase in earnings during the first six months of the year, marking a 67.6% rise. Earnings before interest, taxes, depreciation, and amortisation reached £8.7 million (€10.32 million),

    hVIVO plc

    hVIVO reports strong first half, delivering record revenues and margins

    hVIVO plc (LON:HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced its unaudited interim results for the six-month period ended 30 June 2024.